Makers of pharmaceuticals and high-tech products agreed on a provision in a patent-reform bill under which judges would instruct juries on factors to use in determining appropriate damages for patent infringement. The industries were divided on a proposal that would limit damages to lost profits, or to a "reasonable royalty," further delaying the passage of the bill.

Full Story:

Related Summaries